Introduction
Intensive care unit (ICU) patients experience a loss of fat-free mass of up to 440 g/day, which is associated with increased morbidity and prolonged recovery [1] . In several clinical conditions, low fat-free mass determined by bioelectrical impedance analysis [2] has been associated with worse clinical outcome [3] [4] [5] [6] [7] . However, solid data to support this association in ICU patients are lacking. Only a single retrospective study of 51 ICU patients with acute respiratory failure has reported a correlation between loss of active cell mass and mortality [8] . In a pilot study involving 55 patients that was published in abstract form we observed that phase angle measured at 5 kHz was significantly related to the Sequential Organ Failure Assessment (SOFA) score (r = 0.38, P = 0.03) [9] . Taken together, these studies suggest that phase angle, which reflects fat-free mass, may be useful in predicting morbidity and mortality in ICU patients (Fig. 1) .
Bioelectrical impedance analysis is a well-validated, non-invasive and relatively inexpensive technique to measure body composition [1] . In the ICU, bioelectrical impedance analysis is frequently described as a nonreliable technique to assess nutritional status through body composition, i.e. fat-free mass or fat mass, because of rapid fluid shifts. However, this unreliability is related to the equations used, which have all been validated in clinical situations associated with fluid homeostasis and constant water content. Phase angle is easily, quickly, and repeatedly measured at bedside by bioelectrical impedance analysis. Phase angle reflects intracellular status and fat-free mass ( Fig. 1) , with an altered distribution of intracellular to extracellular water suggested by Conclusion: Low fat-free mass at ICU admission is associated with 28-day mortality. A combined score improves mortality predictability. [10] . Most of these severity-of-disease classification systems are time consuming and suffer some degree of discriminative power (i.e. APACHE II and SAPS II have been validated in or without cardiovascular surgery patients, respectively [11, 12] ).
We conducted an international multicentre prospective observational study in ICU patients to assess the prognosis value of fat-free mass at admission (day 1) measured by bioelectrical impedance analysis-derived phase angle. The primary aim was to determine the association between day 1 phase angle and 28-day mortality. The secondary aim was to determine the relation between day 1 phase angle and disease severity scores (APACHE II and SAPS II).
Methods

Study design
The Phase Angle Project is an international multicentre prospective observational study involving the intensive care departments and nutrition units of ten centres in nine countries: Geneva (Switzerland), Pelotas (Brazil), Brussels (Belgium), Vilnius (Lithuania), Clermont-Ferrand (France), Ljubljana (Slovenia), Palma de Majorque (Spain), Bydgoszcz (Poland), Zagreb (Croatia) and Rouen (France). The project was coordinated by the Nutrition unit, Geneva University Hospital, Geneva, Switzerland, with the first author (RT) as the international study coordinator. The research protocol was approved by the Geneva University Hospitals Ethics Committee, then by the Ethical Committee of each participating hospital. The total number of beds among the participating ICUs was 320, of which 70 % were medical and 30 % surgical beds.
Patients' recruitment
Each participating centre was required to include 100 consecutive patients in the study. Consequently, during the inclusion period each centre enrolled all patients meeting the inclusion criteria until the target of 100 patients was reached. For any one single patient, the study duration was 1 month. The overall enrollment period was from 1 September 2012 to 30 April 2015. The inclusion criteria were: age >18 years, expected length of stay >48 h, absence of pacemaker or heart defibrillator implant, absence of known pregnancy or lactation, affiliation to an health insurance and written informed consent by the patient or her/his next of kin in the case of inability to provide informed consent. Patients were not eligible for entry if they were readmitted within 48 h after their discharge to prevent that a single patient was included twice.
Study endpoints
The primary endpoint was 28-day mortality, i.e. mortality during the 28 consecutive days following ICU admission. If patients were discharged from the hospital or transferred to another healthcare centre, the information on 28-day mortality was collected through an examination of medical records, phone call to the relevant hospital department or to the patient's general physician.
The secondary endpoints were APACHE II and SAPS II scores collected at day 1, which was defined as the day of ICU admission if patients were admitted at or before noon, or as the day following ICU admission if patients were admitted after noon.
Phase angle measurement by bioelectrical impedance analysis
The 50-kHz phase angle was measured by bioelectrical impedance analysis in every patient on day 1 (day 1 phase angle), and the measurement was repeated on day 5 for patients still hospitalised in the ICU. Briefly, after the skin had been cleaned with 70 % ethanol, four adhesive electrodes (3M Red Dot T; 3M Health Care, Borken, Germany) were placed on the dorsal side of the left hand, left wrist, left foot, and left ankle (Fig. 1) while the patient was lying supine with the palms of the hand facing inwards. If the left side was not accessible (e.g. wounds, fracture, among others), the right side was chosen. The phase angle measurement on day 5 was performed with the electrodes in the same position as on day 1. An electrical current of 0.8 mA was produced at 50 kHz by a generator/analyser (Nutriguard M; DataInput Gmbh, Darmstadt, Germany) during an approximately 2 min to measure whole-body resistance (R) and reactance (X c ) [1] . Phase angle was calculated according to the following equation: phase angle (°) = arctan(X c /R) × (180/π) ( Fig. 1 ).
Data collection
Weight and height were measured or obtained by the patient or his/her next of kin during the interview on the day of phase angle measurement by bioelectrical impedance analysis. Body mass index (BMI) was calculated as weight (kg) divided by squared height (m 2 ). Clinical information (primary and secondary admission diagnoses, ICU severity scores, outcomes) was retrieved by each investigator from the hospital electronic medical database. In Geneva University Hospitals, the ICU dedicated computerised information data management system (CliniSoft 6.2, General Electric, Milwaukee, WI) was used.
Statistics
Sample size calculation
The sample size calculation was based on the main endpoint, the 28-day mortality, the recruitment capacity of each centre and the estimation of statistical power. Based on other recent prospective randomised controlled trials [13, 14] and statistics from the ICU department of the Geneva University Hospitals, we expected a 28-day mortality of 15 %. To obtain an area under the receiver operating characteristic (ROC) curve (AUC) assessing 28-day mortality prediction by phase angle of 0.85, and given bilateral α and β risks of 5 and 10 %, respectively, 1000 patients had to be recruited [15] . We therefore decided to include 100 patients per centre.
Statistical analysis
Descriptive statistics were expressed as the mean ± standard deviation or median and interquartile range for continuous data, according to their distribution, and as the number of patients (with the percentage in parenthesis, followed immediately by the counts for the numerator/denominator) for categorical data. ROC curves were used to analyse the association of each variable with 28-day mortality and to find the best cutoff associated with 28-day mortality according to the Youden method. ROC curves were analysed with their AUCs and 95 % confidence intervals (CIs). The discriminative power of the AUC was classified as follows: 0.90 ≤ AUC ≤ 1.0, excellent; 0.80 ≤ AUC < 0.90, good; 0.70 ≤ AUC < 0.80, fair; 0.60 ≤ AUC < 0.70, poor; 0.50 ≤ AUC < 0.60, failure [16] . We analysed 28-day mortality with the χ 2 tests (or Fisher's exact test when appropriate) for categorical data, and the Student's t test (or Mann-Whitney-Wilcoxon test when appropriate) for continuous data. A multivariable logistic regression adjusted for the factors with a P value of <0.2 in the univariate analysis was performed with a backward stepwise elimination process eliminating all variables that did not contribute (P value ≥0.05). For continuous variables, the adjusted odd ratio was expressed for 1-point increase. From this model we computed a risk-score of 28-day mortality. Results are expressed as adjusted odds ratio and their 95 % CI. The risk-score was used in ROC analyses to assess its discriminative power for 28-day mortality. Sensitivity, specificity, positive predictive value and negative predictive value, and their 95 % CI were calculated according to the Youden method. Statistics were computed with STATA V12 (Stata Corp., College Station, TX), and a two-sided P value of <0.05 was considered to be statistically significant.
Results
Patient selection, characteristics and outcomes
Among the 3605 patients who were screened, 1009 patients were initially entered into the study based on the inclusion criteria. Following secondary screenings, 77 (8 %) of these 1009 patients were excluded, leaving a final study population of 931 patients for analysis (26 % of all 3605 patients initially screened) (Fig. 2) . Among the 77 patients excluded during the secondary screenings, 49 (74 %) were excluded because bioelectrical impedance analysis was not performed at admission. The distribution of patients over the different participating hospitals was as follows: Geneva, n = 170; Ljubljana, n = 107; Pelotas, n = 103; Brussels, n = 100; Vilnius, n = 100; Clermont-Ferrand, n = 99; Palma de Majorque, n = 96; Rouen, n = 56; Bydgoszcz, n = 51; Zagreb, n = 49. Patients' characteristics and diagnoses at admission are detailed in Table 1 . Mean day 1 phase angle was 4.5 ± 1.85° (range 1.24°-21.0°). Day 1 phase angle was measured in 932 patients; the data from one patient was excluded due to an aberrant result (day 1 phase angle = 0). As expected, day 1 phase angle was lower in older patients, in female patients and in patients with a lower BMI (data not shown). SAPS II scores were available for 657 patients as SAPS II data are not routinely collected in two centres. Patients' clinical outcomes during the follow-up period are shown in Table 1 .
Relation between day 1 fat-free mass and 28-day mortality
The 28-day mortality was 19.3 % (180/931; range 9.6-38.8 %), which is close to the 15 % mortality predicted for the sample size calculation. Day 1 phase angle was lower in non-survivors than in survivors (Table 1 ; Fig. 3a ), but this difference failed to reach statistical significance at day 5 in the 527/931 patients (57 %)
Screened, n=3605
Included, n=1009 (Fig. 3b) , indicating a poor discriminative power of day 1 phase angle. The 28-day mortality was higher in patients with day 1 phase angle of <3.49 (31 %, 86/275) than in those with a day 1 phase (Fig. 4) , which improved the discriminative power of the day 1 phase angle values or the APACHE II or SAPS II values alone.
Relation between day 1 phase angle and ICU severity scores
There was a correlation between day 1 fat-free mass and ICU severity scores. APACHE II and SAPS II values were significantly higher in patients with a day 1 phase angle of <3.49 than in patients with a day 1 phase angle of ≥3.49 (APACHE II scores: 21.8 ± 9.2 vs. 17.7 ± 8.7, P < 0.001; SAPS II: 48.0 ± 19.2 vs. 40.5 ± 18.3, P < 0.001).
Discussion
In this international multicentre prospective observational study, a low fat-free mass measured by bioelectrical impedance analysis-derived phase angle at ICU admission was associated with increased 28-day mortality. A multivariable combined score (including day 1 phase angle, APACHE II and other parameters) improved the discriminative power of 28-day mortality compared to either of the day 1 phase angle or APACHE II or SAPS II values alone. The results of this study suggest that phase angle could be used as one of a battery of prognosis markers at ICU admission. In non-ICU patients, bioelectrical impedance analysis is a well-validated and easy-to-use method to measure body composition at bedside, including fat-free mass, fat mass and total, intra-and/or extracellular body water. It is also provides an easy and quick measurement of phase angle that is a reflection of fat-free mass. A low phase angle reflects fat-free mass loss and cell dysfunction, whereas a higher value (>6 in normal subjects [17] ) reflects good cell health or nutritional status (Fig. 1) . Low phase angle has been correlated with a worse disease prognosis in oncology [5, [18] [19] [20] [21] , human immunodeficiency virus infection [6] , amyotrophic lateral sclerosis [22] , geriatric [23] , renal dialysis in chronic renal failure [24] , liver cirrhosis [25] , acquired immune deficiency syndrome [26] and gastrointestinal surgical patients [27] . The phase angle cutoff associated with increased mortality is variable, being reported as <2.5° in amyotrophic lateral sclerosis [22] , <3.5° in geriatrics [23] , from <1.65° to <5.6° in oncology [18] [19] [20] [21] , <5.4° in cirrhosis [25] and in our study <3.49° at ICU admission. These differences among cutoffs could be explained by the lack of homogeneity between the different study populations. The relation of fat-free mass loss, defined as a low phase angle, with prognosis and illness severity reinforces the interest in using bioelectrical impedance analysis for the clinical management of patients with acute (e.g. ICU) or chronic disease.
In our study the relationship between fat-free mass and mortality failed to reach statistical significance on day 5. No single explanation is available. This result could be related to the reduction in the size of the study sample on day 5 due to early discharge from the ICU. However, a significant relationship between day 5 fat-free mass and mortality was expected. Indeed, during the early phase of the ICU stay (i.e. the first 96 h), critically ill patients suffer a loss of fat-free mass of up to 440 g/day, which is associated with increased morbidity and prolonged recovery [1] . One could hypothesise that patients with fat-free mass loss at day 5 should suffer more from functional impairment or ICU-acquired weakness [28] [29] [30] or could be at increased risk of late mortality (post-28-day).
In our study, APACHE II or SAPS II values had a poor/ fair discriminative value to predict 28-day mortality, with AUCs which were much below the values reported in the validation studies of these ICU severity scores [11, 12] . This result could be explained by the lower sample size or by the patient selection process: in the APACHE II validation study, only cardiac surgery patients were enrolled [11] and in the SAPS II validation study, patients with coronary care or cardiac surgery were excluded [12] ; in contrast, our ICU population was mixed, of whom 6 % were cardiac patients. Interestingly, in our study, the mortality predictability of either day 1 phase angle, SAPS II or APACHE II alone was much improved by a multivariable model including day 1 phase angle and APACHE II scores, among other variables. This result indicates that phase angle, a marker of fat-free mass, illness severity and cell health, improves mortality predictability of the ICU severity scores. These ICU severity scores are based on clinical and biological data that cannot strictly reflect an alteration of cell functions, as does the phase angle. Moreover, phase angle values are dependent on gender, age and nutritional status, with the phase angle being lower in female and older patients, and in patients with loss of fat-free mass, i.e. malnourished [17] . Therefore by combining ICU severity scores with a marker of fatfree mass loss, whatever the aetiology (disease severity, chronic diseases, ageing, among others), the prognostic value could be improved.
Phase angle is calculated from two clinical parameters only, namely, reactance and resistance, which reflect the electrical properties of body cells. As such, phase angle may be less dependent on fluid variations than the standard body composition equations. However, it may be speculated that in patients admitted to the ICU rapid fluid shifts, overhydration or dehydration status could contribute to cell damage and therefore be associated with a decreased phase angle. Further studies are needed to better assess the relation between BMI, body composition (including water compartments) and phase angle in ICU patients.
Another applicability of bioelectrical impedance analysis in the ICU could be the bioelectrical impedance vector analysis (BIVA). Indeed, Jones et al. showed that repeated BIVA hydration measurements could detect fluid accumulation or fluid balance of >2 L in ICU patients [31] . However, further studies are also needed to better define the roles of bioelectrical impedance analysis-derived phase angle and BIVA in the management of ICU patients.
In our study, patients with a pacemaker or implantable cardioverter defibrillators were excluded from the study in accordance with the latest European Society for Clinical Nutrition and Metabolism guidelines [2] . However, two studies [32, 33] have proven that bioelectrical impedance analysis can be safely performed in patients equipped with implantable cardioverter defibrillators.
Our study has a number of limitations. We planned to analyse 1000 patients on a basis of 100 patients per centre, but due to secondary exclusions, only 931 patients were analysed, and due to missing data in 3.9 % of these latter patients, the multivariable analysis was performed in 895 patients. Phase angle was shown to be predictive of 28-day mortality in the ICU population, known to have rapid fluid shifts. The exact role of these fluid shifts on the observed findings remains to be determined. As previously reported [31] , bioelectrical impedance analysis could not always be systematically performed under the best conditions, namely, in those who could not be positioned in a full supine position due to clinical constraints (e.g. those with head injury and intracranial pressure monitoring) and in those whose for whom the positioning of the electrodes had to be modified slightly because of the presence of other devices (e.g. intravenous cannulas and soft restraints).
In conclusion, fat-free mass loss, measured at ICU admission by bioelectrical impedance analysis-derived phase angle, is associated with 28-day mortality. Day 1 phase angle, APACHE II and SAPS II each has a poor discriminative power when used alone. A multivariable combined score improves 28-day mortality predictability. Bioelectrical impedance analysis-derived phase angle could be used as a marker of illness severity in the ICU patients. As fat-free mass loss, i.e. low phase angle, defines malnutrition, future studies may be designed to assess whether nutritional interventions targeted to phase angle values could change patients' outcome.
